Journal Article Summary
The article investigates how patients in the United States and Europe understand and access low-dose aspirin for preventing cardiovascular disease (CVD). This topic is significant because aspirin is commonly used for CVD prevention, but its effectiveness and safety can vary based on individual risk factors and the context of its use. The study highlights the need for better patient education regarding the risks and benefits of aspirin, especially since many patients may not fully grasp their own cardiovascular risk or the appropriate indications for aspirin therapy.
The researchers conducted a survey among adults aged 50 and older with at least one cardiovascular risk factor, gathering responses from 300 participants across two sites—one in the U.S. and one in Europe. The findings revealed that a large portion of participants were unaware of their 10-year CVD risk, with many not knowing the benefits and risks associated with aspirin use. Specifically, 54% of participants did not know their CVD risk, and a significant number overestimated the benefits of aspirin while underestimating its bleeding risks. Additionally, most U.S. participants accessed aspirin over the counter, while in Europe, it was primarily obtained through prescriptions.
The study has several limitations, including reliance on self-reported data and a convenience sample from specific clinics, which may not represent the broader population. Patients should be aware that many do not understand the differences between primary and secondary prevention of CVD and the implications of aspirin use. It is crucial for individuals to discuss their aspirin use and cardiovascular risk with healthcare professionals to make informed decisions about their treatment options. The findings suggest that a more regulated approach to aspirin access, similar to that in Europe, may enhance patient safety and understanding.
Medication Safety Note
This journal article summary is provided for educational purposes only and is not medical advice. Always consult a licensed healthcare professional before starting, stopping, or changing any medication.
Article Cited
- Jacobsen Alan P., Lim Zi Lun, Chang Blair, Lambeth Kaleb D., Das Thomas M., Gorry Colin, McCague Michael, Sharif Faisal, et al.. Contextualizing National Policies Regulating Access to Low‐Dose Aspirin in America and Europe Using the Full Report of a Transatlantic Patient Survey of Aspirin in Preventive Cardiology. Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease 2022. DOI: 10.1161/JAHA.121.023995. PMID: 35411788. PMCID: PMC9238454.
Featured Pill Pals Product
OTC 1000 (1,000) Count Low Dose Aspirin 81mg for Adults and Children 12 years and over --- Generic For Bayer Low Dose --- Time Cap Labs
1000 (1,000) Count Low Dose Aspirin 81mg for Adults and Children 12 years and over --- Generic For Bayer Low Dose --- Time Cap Labs is available through Pill Pals Pharmacy with cash-pay pharmacy pricing and free shipping where available. No prescription required for eligible over-the-counter purchases.
